ARTICLE | Clinical News
HCT-1026: Began Phase II trial
April 24, 2000 7:00 AM UTC
NicOx S.A. (NM:Nicox), Sophia-Antipolis, France Product: HCT-1026 Business: Musculoskeletal Therapeutic category: NSAID, Nitric oxide Target: Osteoclasts Description: Nitro-derivative of flurbiprofen ...